Pfizer Pricing Data Subpoenaed By GAO As Part Of Medicaid Investigation
Executive Summary
Pfizer has until Jan. 14 to respond to the General Accounting Office's request for documents related to price reporting practices under the Medicaid drug rebate program
You may also be interested in...
Schering, Pfizer Responding To Investigations Of Managed Care Deals
Schering-Plough is responding to a grand jury subpoena issued in March by the Philadelphia U.S. Attorney's Office focusing on whether "nominally priced" products and other free goods should have been included in Medicaid rebate calculations
Schering, Pfizer Responding To Investigations Of Managed Care Deals
Schering-Plough is responding to a grand jury subpoena issued in March by the Philadelphia U.S. Attorney's Office focusing on whether "nominally priced" products and other free goods should have been included in Medicaid rebate calculations
Pfizer supplies pricing data to GAO
Pfizer is turning over drug pricing data subpoenaed by the General Accounting Office, Pfizer CEO Henry McKinnell, PhD, reported Jan. 15. GAO's Jan. 3 subpoena gave the company until Jan. 14 to supply the documents (1"The Pink Sheet" Jan. 14, p. 26). "What was requested was pricing of individual products to individual customers," McKinnell said. "We were prepared to provide that information. However, we wanted to protect confidentiality. We agreed to those protections last week and the data has been provided"...